



## Humacyte Announces First Symvess™ Sale to Military Treatment Facility

*Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency*

*Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities*

DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today the first sale of Symvess to a U.S. Military Treatment Facility. The facility is a state-of-the-art medical complex located on a major U.S. military base that provides health care to approximately 200,000 active-duty service personnel, retirees, and their family members.

This sale follows the recent ECAT listing approval from the U.S. Defense Logistics Agency. ECAT is an internet system that provides the Department of Defense (DOD) and other federal agencies with access to manufacturers' and distributors' products. The ECAT approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at approximately 35 Military Treatment Facilities and approximately 160 U.S. Department of Veterans Affairs hospitals.

Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024.

"We are excited to see the first purchase and use of Symvess by a military treatment facility," said Dr. Laura Niklason, President and CEO of Humacyte, Inc. "We have great interest in improving the medical options available to healthcare professionals treating military personnel and their families, and look forward to advancing our discussions with additional DOD hospitals."

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for use or sale by the FDA or any other regulatory agency.

### About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing an innovative biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues designed to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit [www.Humacyte.com](http://www.Humacyte.com).

### Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize our ATEV in the United States under the brand name Symvess in vascular trauma repair; the anticipated characteristics and performance of our ATEVs; and the anticipated benefits of the ATEV relative to existing alternatives. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and the Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte's control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

### Humacyte Investor Contact:

Joyce Allaire

LifeSci Advisors LLC

+1-617-435-6602

[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)

[investors@humacyte.com](mailto:investors@humacyte.com)

**Humacyte Media Contact:**

Rich Luchette

Precision Strategies

+1-202-845-3924

[rich@precisionstrategies.com](mailto:rich@precisionstrategies.com)

[media@humacyte.com](mailto:media@humacyte.com)



Source: Humacyte, Inc